Sanofi’s Immuneering IMRX Stock Holding History

Sanofi’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.3M	Hold	2,708,559	–	–	4.25%	7
2025 Q4	$17.8M	Hold	2,708,559	–	–	5.74%	5
2025 Q3	$19M	Buy	+2,708,559	New	+$14.1M	7.28%	5

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Sanofi's IMRX Position: Q1 2026 in Review

Sanofi held its Immuneering (IMRX) position steady in Q1 2026 at 2,708,559 shares worth $14.3M. The position accounts for 4.25% of the portfolio, ranked #7.

Sanofi first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $19M in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Sanofi held 2,708,559 shares of Immuneering worth $14.3M as of Q1 2026.
Sanofi left its Immuneering share count unchanged in Q1 2026.
Immuneering made up 4.25% of Sanofi's portfolio in Q1 2026, its #7 holding.
Sanofi first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
Sanofi's Immuneering position peaked at $19M in Q3 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Sanofi's 13F filing for Q1 2026, filed 7 May 2026.